Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2020 / Article

Research Article | Open Access

Volume 2020 |Article ID 6937186 | https://doi.org/10.1155/2020/6937186

Yang Ma, Wenjun Wang, Jiani Yang, Sha Zhang, Zhe Li, Fei Li, Shaojie Huang, Lu Lei, Kai Wang, Aidong Wen, Yi Ding, "A Network Pharmacology Technique to Investigate the Synergistic Mechanisms of Salvia miltiorrhiza and Radix puerariae in Treatment of Cardio-Cerebral Vascular Diseases", Evidence-Based Complementary and Alternative Medicine, vol. 2020, Article ID 6937186, 18 pages, 2020. https://doi.org/10.1155/2020/6937186

A Network Pharmacology Technique to Investigate the Synergistic Mechanisms of Salvia miltiorrhiza and Radix puerariae in Treatment of Cardio-Cerebral Vascular Diseases

Academic Editor: Riaz Ullah
Received08 Jan 2020
Accepted27 Jul 2020
Published05 Oct 2020


Objective. This study is aimed to analyze the active ingredients, drug targets, and related pathways in the combination of Salvia miltiorrhiza (SM) and Radix puerariae (RP) in the treatment of cardio-cerebral vascular diseases (CCVDs). Method. The ingredients and targets of SM and RP were obtained from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), and the disease targets were obtained from Therapeutic Target Database (TTD), National Center for Biotechnology Information (NCBI), and Online Mendelian Inheritance in Man (OMIM) Database. The synergistic mechanisms of the SM and RP were evaluated by gene ontology (GO) enrichment analyses and Kyoto encyclopedia of genes and genomes (KEGG) path enrichment analyses. Result. A total of 61 active ingredients and 58 common targets were identified in this study. KEGG pathway enrichment analysis results showed that SM- and RP-regulated pathways were mainly inflammatory processes, immunosuppression, and cardiovascular systems. The component-target-pathway network indicated that SM and RP exert a synergistic mechanism for CCVDs through PTGS2 target in PI3k-Akt, TNF, and Jak-STAT signaling pathways. Conclusion. In summary, this study clarified the synergistic mechanisms of SM and RP, which can provide a better understanding of effect in the treatment of CCVDs.

1. Introduction

Cardio-cerebral vascular diseases (CCVDs) seriously threaten human health and life for the high occurrence and mortality [1]. Severe sequelae, complicated symptoms, and difficulties in treatment are markedly characteristics of CCVDs. CCVDs include cerebrovascular diseases and cardiovascular diseases, and about 40% of middle-aged and elderly people are suffering from hyperglycemia, hyperlipidemia, and hypertension [2]. Therefore, it is of great clinical significance to formulate effective treatment strategies for the significant characteristics of CCVD such as severe sequelae, complex symptoms, and difficult treatment [3].

Salvia miltiorrhiza (SM), a Traditional Chinese Medicine (TCM), has been widely used in the treatment of CCVDs [4]. Radix puerariae (RP) is one of the earliest medicinal materials used in ancient China, and the effects on CCVDs in the elderly have been reported [5]. The combination of SM and RP exerts synergistic effect on CCVDs. Studies have shown that SM and RP are well tolerated in the treatment of cardio-cerebral vascular diseases and can improve neointimal hyperplasia, vascular function, and structure and significantly improve the occurrence of atherosclerosis and hypertension [6, 7].

SM has been extensively used in Asian countries against CCVDs. The primary active ingredients of SM are water-soluble phenolic acids represented by salvianolic acid B and fat-soluble ketones represented by tanshinone IIA. In previous studies, it has been proved that SM has improved microcirculation, inhibition of platelet aggregation, and antioxidation [8, 9]. RP also showed significant effects on senile cerebrovascular disease, cardiovascular disease, and neurodegenerative diseases [10, 11]. SM and RP were applied in blood stasis, and RP promoted vascular smooth muscle movement and blood circulation. SM can remove blood stasis and blood slow flow caused by blood stasis to ensure blood flow unimpeded. SM and RP can synergistically affect CCVDs [12]. Lam et al. [13] have demonstrated SM and RP can potentially improve cerebrovascular circulation. However, the mechanism of action of SM and RP is not clear.

The network pharmacology approaches, concentrated on analyzing the network connectivity and dynamics as ingredients of drug targets and designing the optimal therapeutic strategies, can expose the underlying complex relationships between the herbal formula and the whole body [14]. Coincidentally, almost all Chinese medicines and ethnic medicine around the world work by targeting multiple molecules on the human body [15]. It takes advantage of advancements in systems biology, a high degree of integration data analysis strategy, and interpretable visualization provides deeper insights into the underlying mechanisms of TCM theories, including the principles of herb combination, biological foundations of herb or herbal formulae action, and molecular basis of TCM syndromes [16]. In this study, the mechanism of SM and RP on CCVDs was studied by the network pharmacology method, which provided a theoretical basis for the further research of SM and RP. Figure 1 is the network pharmacology analysis workflow.

2. Materials and Methods

2.1. Active Ingredients of SM and RP

It is useful to explore the molecular mechanisms based on pharmacokinetics characteristics [17]. SM and RP are mostly used by oral administration in the clinic; therefore, pharmacokinetics parameters such as oral bioavailability (OB) and drug-likeness (DL) were investigated. OB is commonly used to measure whether oral drugs can be through obstacles as well as be transported into the systemic blood circulation. DL is mainly used to predict exactly how “drug like” an ingredient is, which helps to assist pharmacokinetic and pharmaceutical properties, for example, solubility and chemical stability [18]. The active ingredients of SM and RP were gathered from TCMSP [19] (https://tcmspw.com/tcmsp.php), a phytochemical database, with the keywords “Salvia miltiorrhiza” and “Radix puerariae”. The OB and DL of chemical ingredients of SM and RP were collected from TCMSP. In this study, screening standard was set to OB ≥ 30% and DL ≥ 0.18, and chemical ingredients lower than this standard were eliminated from the final list of active ingredients of SM and RP.

2.2. Ingredient Targets of SM and RP

All proteins related to the active ingredients were obtained from the TCMSP databases. Protein names of SM- and RP-related protein were unified to official target name by UniProt [20] (https://www.uniprot.org/), with limitation to “Homo sapiens.” Subsequently, protein names were transformed into official target name and duplicates were deleted.

2.3. Targets of CCVDs

Disease association targets were acquired from the TTD [21] (http://bidd.nus.edu.sg/group/cjttd/), NCBI [22] (https://www.ncbi.nlm.nih.gov/gene) and the OMIM [23] (http://www.omim.org/) database, and merely, “Homo sapiens” proteins connected to CCVDs were chosen. UniProt was used to unify the name of target associated with CCVDs because the target information of the disease is derived from different databases and has a nonstandardized name, and the duplicates were deleted. Active ingredients and disease targets were uploaded into the Veeny 2.1 (http://bioinfogp.cnb.csic.es/tools/venny/) website to obtain common targets of active ingredients and disease.

2.4. GO and KEGG Enrichment Analysis

Common targets of ingredients and disease were uploaded to Visualization and Integrated Discovery (David) [24] variation 6.8 (https://david.ncifcrf.gov/), and the species was set as “Homo sapiens” for GO and KEGG enrichment analysis. Among them, GO enrichment analysis includes three parts: cellular component (CC), biological process (BP), and molecular function (MF). A histogram was drawn according to the analysis results.

2.5. Common Target PPI Network Construction

The protein-protein interaction (PPI) information was obtained from the Search Tool for the Retrieval of Interacting Genes [25] (STRING, https://string-db.org/) database by uploading the common targets with the species limited as “Homo sapiens” (human) and “minimum required interaction score: highest confidents (0.900)”. Other parameters remain the default settings, and the interactive relationship will be obtained. PPI network was drawn by importing the interaction information in Cytoscape 3.6.1; thereafter, topological parameter was examined by using the network analyzer in the software.

2.6. Construction of Active Ingredient-Target-Pathway Network

The targets involved in the main pathways were listed, and duplicates were removed and ligated with the active ingredients of SM and RP. The active ingredient-target-pathway network was constructed with Cytoscape 3.6.1 software.

3. Results

3.1. Active Ingredients and Target Acquisition of SM and RP

In SM and RP, 61 active ingredients and 176 targets were obtained from TCMSP. The resulting compound-target network is shown in Figures 2(a)2(c), respectively. Figure 2(d) shows that there are 68 common targets in SM and RP. The active ingredients information about SM and RP is shown in Table 1. The structural formula was drawn with ChemDraw software. Active ingredients information is presented in Supplementary Table S1. The structure of active ingredients data is provided in Supplementary Document 1.

Mol idComponentsStructureOB (%)DL (%)

SM MOL0016011,2,5,6-Tetrahydrotanshinone38.750.36
MOL002651Dehydrotanshinone II A43.760.4
MOL007048(E)-3-[2-(3, 4-Dihydroxyphenyl)-7-hydroxy-benzofuran-4-yl]acrylic acid48.240.31
MOL007063Przewalskin a37.110.65
MOL007064Przewalskin b110.320.44
MOL007068Przewaquinone B62.240.41
MOL007069Przewaquinone c55.740.4
MOL007070(6S, 7R)-6,7-Dihydroxy-1,6-dimethyl-8,9-dihydro-7H-naphtho[8,7-g]benzofuran-10,11-dione41.310.45
MOL007071Przewaquinone f40.310.46
MOL007081Danshenol B57.950.56
MOL007082Danshenol A56.970.52
MOL007093Danshexinkum d38.880.55
MOL007111Isotanshinone II49.920.4
MOL007119Miltionone I49.680.32
MOL007120Miltionone II71.030.44
MOL007124Neocryptotanshinone ii39.460.23
MOL007130Prolithospermic acid64.370.31
MOL007132(2R)-3-(3,4-Dihydroxyphenyl)-2-[(Z)-3-(3,4-dihydroxyphenyl)acryloyl]oxy-propionic acid109.380.35
MOL007141Salvianolic acid g45.560.61
MOL007142Salvianolic acid j43.380.72
MOL007143Salvilenone I32.430.23
MOL007151Tanshindiol B42.670.45
MOL007152Przewaquinone E42.850.45
MOL007154Tanshinone iia49.890.4
MOL007156Tanshinone ?45.640.3
RP MOL000392Formononetin69.670.21
MOL012297Puerarin [5]24.030.39

3.2. CCVDs Target Acquisition

The targets of disease gained from the TTD, NCBI, and OMIM databases. These targets were uploaded into the UniProt database for correction, and 623 targets were included after the deletion of the duplicates. The targets of the active ingredients and disease were used to acquire the common target through the Veeny 2.1 website. These targets are both targets of drug and disease. Therefore, SM and RP are likely to play a salutary role through these targets. Disease target information is provided in Supplementary Table S2. Disease-drug common targets data are provided in Supplementary Table S3.

3.3. GO Enrichment Analysis

GO enrichment analysis result was obtained from the David database. The top five count value was selected (Table 2) to draw the histogram (Figure 3(a)). The results showed that, with the enrichment results of BP, the target of SM and RP treatment of CCVDs was generally associated with the policy of RNA polymerase II promoter transcription, DNA template transcription, and cell proliferation. According to the enrichment consequence of CC, the target of SM and RP in treating CCVDs was mainly focused on the extracellular space, plasma membrane, and extracellular exosomes. From the results of MF enrichment, the effect of SM and RP on the treatment of CCVDs is mainly zinc ion binding, serine endopeptidase activity, and sequence-specific DNA binding. GO analysis data are provided in Supplementary Table S4 (sheet1, sheet2, and sheet3).

GO enrichmentCount

MFZinc ion binding9
Transcription factor activity and sequence-specific DNA binding8
Serine-type endopeptidase activity7
Sequence-specific DNA binding7
DNA binding7
CCExtracellular space21
Plasma membrane13
Extracellular exosome12
Integral component of plasma membrane10
Cell surface8
BPPositive regulation of transcription from RNA polymerase II promoter13
Transcription, DNA templated8
Positive regulation of ERK1 and ERK2 cascades7
Positive regulation of cell proliferation7
Positive regulation of transcription, DNA-templated7

3.4. KEGG Pathway Enrichment Analyses

The KEGG analysis results from the David database; the top 15 count value was selected and the specific data, as shown in Table 3. A histogram was drawn, and the results are presented in Figure 3(b). The KEGG analysis results were imported in the Cytoscape software. The results are shown in Figure 3(c). It can display in table that it includes inflammatory processes and immunosuppression (such as TNF signaling pathway), cardiovascular systems (such as PI3K-Akt and JaK-STAT signaling pathway) and neuroactive ligand-receptor interaction. The principal processes of SM and RP in the treatment of CCVDs consist of signaling paths such as PI3K-Akt, TNF, and JaK-STAT signaling pathway. KEGG pathway analysis data are provided in Supplementary Table S4 (sheet4).

KEGG pathwayNumber of targetsCount

Pathways in cancerIL6, AR, PTGS2, PDGFA, MMP9, PPARG, TP53, MMP2, TGFB1, MMP1, STAT3, AGTR1, HIF1A, VEGFA, F2R15
Neuroactive ligand-receptor interactionAGTR1, ADRB2, DRD2, CHRM2, LEPR, F2, ADRA1A, NR3C1, HTR2C, F2R, HTR2A11
Proteoglycans in cancerHIF1A, TNF, MMP9, VEGFA, ESR1, TP53, MMP2, TGFB1, STAT39
PI3K-Akt signaling pathwayIL4, IL6, PDGFA, CHRM2, VEGFA, TP53, NOS3, JAK3, F2R9
Calcium signaling pathwayAGTR1, ADRB2, CHRM2, ADRA1A, NOS3, HTR2C, F2R, HTR2A8
HTLV-I infectionVCAM1, ICAM1, IL6, TNF, PDGFA, TP53, JAK3, TGFB18
Inflammatory bowel disease (IBD)IL4, IL6, TNF, IFNG, TGFB1, IL10, STAT37
Rheumatoid arthritisICAM1, IL6, TNF, IFNG, VEGFA, TGFB1, MMP17
HIF-1 signaling pathwayIL6, HIF1A, IFNG, EDN1, VEGFA, NOS3, STAT37
TNF signaling pathwayVCAM1, ICAM1, IL6, TNF, PTGS2, MMP9, EDN17
Jak-STAT signaling pathwayIL4, IL6, LEPR, IFNG, JAK3, IL10, STAT37
Cytokine-cytokine receptor interactionIL4, IL6, TNF, LEPR, IFNG, TGFB1, IL107
African trypanosomiasisVCAM1, ICAM1, IL6, TNF, IFNG, IL106
LeishmaniasisIL4, TNF, PTGS2, IFNG, TGFB1, IL106

3.5. Component-Target-Pathway Network Analyses

The targets involved in PI3K-Akt, TNF, and JaK-STAT signaling pathway were listed and removed the duplicates, and the results were as follows: IL4, IL6, PDGFA, CHRM2, VEGFA, TP53, NOS3, JAK3, F2R, VCAM1, ICAM1, TNF, PTGS2, MMP9, EDN1, LEPR, IFNG, IL10, and STAT3, a total of 19 targets. Then, find these targets and refer to the ingredients using Cytoscape 3.6.1 software to construct an ingredient-target-pathway network, as shown in Figure 4.

Figure 4 shows the ingredient-target-pathway network. The blue diamond represents the target, the red diamond represents the cotarget, the yellow hexagon represents the SM active component, the green hexagon represents the RP active component, and the pink rectangle represents the pathway.

3.6. Common Target PPI Network Constructions

The interactive relationship of protein-protein was obtained through the STRING database, and then the target protein PPI network map was drawn by Cytoscape 3.6.1, as shown in Figure 5. The network consists of 58 nodes with 130 edges, an average degree of 4.48, and a PPI enrichment value: <1.0e−16. In the figure, the greater the degree, the bigger the node.

4. Discussion

TCM usually plays a multi-ingredient and multipathway synergistic effect against various diseases. Many research studies have shown that network pharmacology has made great improvement in exploring the application of active ingredients, targets, and systems in TCM [26, 27]. Therefore, this research method applied to TCM should correspond to the synergistic mechanism. In this study, we applied a network pharmacology approach to investigate the related targets and pathways of the combination of SM and RP against CCVDs, thereby illuminating the synergistic mechanism of SM and RP on CCVDs.

In this study, the network pharmacology method was conducted to explore the synergistic effect of SM and RP on CCVDs to enhance the accuracy of target forecast to some extent. We found 61 active ingredients in SM and RP and 58 targets related to CCVDs. Based on the outcomes of pathway enrichment, SM and RP active ingredients can simultaneously target cancer pathways, neuroactive ligand-receptor interactions, and PI3K-Akt and TNF signaling pathways, leading to the synergistic effect of SM and RP. Furthermore, depending on the PPI system analysis, STAT3, APP, EDN1, TNF, AGTR1, VEGFA, IL6, F2, MMP9, and HTR2C were recognized as the center targets. These targets are synergistic targets of SM and RP treatment of CCVDs.

In the PPI system analysis, STAT3, APP, EDN1, TNF, AGTR1, VEGFA, IL6, F2, MMP9, and HTR2C were considered to be crucial targets. TNF, a cytokine related to a severe stage of systemic inflammation, is substantially raised in patients with ischemic and hemorrhagic stroke [28]. Besides, VEGFA is a member of the VEGF family of proteins [29]. VEGFA has proangiogenic and neuroprotective effects that induce neurogenesis [30] and is increasingly important in the systemic treatment of CCVDs [31]. IL6 is a cytokine originated from T cells and macrophages that has been involved in many types of biological activities such as the formation the severe phase responses and regulation of the organic immune system, and it is related to the metabolic processes during exercise [32]. Primary studies showed that IL6 is the best proinflammatory biomarker in case of stroke [33]. IL6 can also be activated by immune effect damaged by ischemia reperfusion (I/R) [34]. MMPs are well-known mediators of cardiovascular pathophysiology. MMP9 is an important mediator of cardiac remodeling after MI and is centrally involved in inflammation and repair components of the response [35].

GO and KEGG analysis was performed to better understand the interaction of targets. In the result, GO analysis exposed that the target is mainly involved in transcriptional favorable policy of RNA polymerase II promoter, transcription, DNA template, positive policy of ERK1 and ERK2 cascades, and biological processes of and biological processes of negative policy of cell proliferation; the molecular practical body is primarily managed by zinc ion binding, transcription factor activity, serine endopeptidase activity, sequence-specific DNA binding, and so forth. Cell partial analysis revealed that the extracellular area represented the largest proportion, followed by the plasma membrane, extracellular exosomes, the integral components of the plasma membrane, and the cell surface. Interestingly, KEGG pathway analysis is mostly involved in neuroactive ligand-receptor interactions, PI3K-Akt, TNF, and Jak-STAT signaling pathways, which are consistent with previous reports that are involved in the progression of key features in CCVDs.

The phosphatidylinositol 3-kinase (PI3K-Akt) pathway plays an essential role in intracellular signal transduction involved in cell proliferation, cell survival, inflammation, and metabolism [36]. Neuronal apoptosis is the main performance of cell death following cerebral ischemia. One of the important cellular mechanisms, the balance between apoptosis and antiapoptotic signals, figures out the fate of nerve cells after cerebral I/R [37]. There is evidence showed that the PI3K-Akt pathway can be activated to regulate cell apoptosis and cerebral I/R injury, thereby playing a significant neuroprotective effect [38, 39]. Studies have shown that inhibiting AKT phosphorylation attenuates neuronal apoptosis against cerebral I/R injury [40, 41]. Studies have shown puerarin and tanshinone IIA synergistic effect on the PI3K-Akt pathway to protect CCVDs [42, 43]. TNF signaling pathway can promote the expression of proinflammatory cytokines, chemokines, growth factors, and TNF-α itself to amplify the inflammatory response and immune effects [44]; Janus kinases/signal transducer and activator of transcription (Jak-STAT) signaling pathway is a crucial signaling pathway in cells, which is involved in mediating cardiomyocyte growth, development, apoptosis, and regulation of angiogenesis. Cagnin et al. [45] show that microarray and meta-analysis of human coronary atherosclerotic plaque modification gene expression discovered that the Jak-STAT pathway plays an important role in cardiovascular protection. As shown in Figure 4, the highest value of the degree of the target interacting with the ingredients is PTGS2. In addition, PTGS2, called cyclooxygenase 2, is an important enzyme in the biosynthesis of prostaglandins, which has both a dioxygenase and a peroxidase [46]. Thus, SM and RP synergistically effect with PI3K-Akt, TNF, and Jak-STAT signaling pathways and PTGS2 targets to treat CCVDs.

In summary, this study explored the related diseases and complex diseases from the perspective of systemic pharmacology to identify active ingredients and improve cognition of the effective mechanism of TCM. We mainly from the following aspects to study the synergistic effects of SM and RP on CCVDs, such as the active ingredients in SM and RP, related targets, signal pathways, and biological processes involved in the related targets. In general, all nodes in the PPI network directly or indirectly affect the pathological process of CCVDs. Through the ingredient-target-pathway network, it was found that SM and RP play a synergistic therapeutic role mainly through PTGS2 target and PIK3-Akt, HIF-1, Jak-STAT, and TNF signaling pathways. This study first theoretically explained the synergistic therapeutic effect of SM and RP on CCVDs and further explained the principles of compatibility of TCMSP. On the other hand, it explored the active ingredients, targets, and pathways of SM and RP in the treatment of CCVDs to illustrate the synergistic effect, and it also provided reference for further study of pharmacology experiment of CCVDs treatment and other related studies of TCM.

Data Availability

The data used to support the findings of this study are included within the article and the supplementary information files.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Yang Ma, Wenjun Wang, and Jiani Yang contributed equally to this work.


This study was supported by the Booster Plan of Xijing Hospital (XJZT18D06), the Foundation of Shaanxi Administration of Traditional Chinese medicine (2019-GJ-ZY006), and the Foundation of Subject Innovation Team of Shaanxi University of Chinese Medicine (2019-YS01).

Supplementary Materials

Table S1 (sheet1): the active ingredients in SM and RP. Chemname was obtained from TCMSP. Table S1 (sheet2): corrected protein name. Entry was converted to gene name by UniProt. Table S1 (sheet3): SM and RP have common targets. Table S2: targets related to CCVDs. All targets from the TTD, NCBI gene, and OMIM database. Table S3: common targets of disease and drug. Table S4 (sheet1–sheet3): GO enrichment analysis: biological process (BP), cellular component (CC), and molecular function (MF). Table S4 (sheet4): KEGG pathway enrichment analysis. All data are from DAVID database. Supplementary Document 1: the structure of active ingredients data. (Supplementary Materials)


  1. Y. Y. Li, Y. T. Liu, Y. Xia et al., “Pharmacological effects and mechanisms of Chinese medicines modulating NLRP3 inflammasomes in ischemic cardio/cerebral vascular disease,” The American Journal of Chinese Medicine, vol. 46, no. 08, pp. 1721–1741, 2018. View at: Publisher Site | Google Scholar
  2. N. Han, H. Fang, and R. Niu, “Clinical effect analysis of danhong injection in treating apoplexy cardiovascular and cerebrovascular diseases,” in Proceedings of the AIP Conference, vol. 2110, 20057 pages, AIP Publishing, College Park, MD, USA, June 2019. View at: Google Scholar
  3. V. Jacob, A. B. Thota, S. K. Chattopadhyay et al., “Cost and economic benefit of clinical decision support systems for cardiovascular disease prevention: a community guide systematic review,” Journal of the American Medicine Informatics Association, vol. 24, no. 03, pp. 669–676, 2017. View at: Google Scholar
  4. Z.-M. Li, S.-W. Xu, and P.-Q. Liu, “Salvia miltiorrhizaBurge (danshen): a golden herbal medicine in cardiovascular therapeutics,” Acta Pharmacologica Sinica, vol. 39, no. 5, pp. 802–824, 2018. View at: Publisher Site | Google Scholar
  5. S. Zhang, J. Wang, H. Zhao et al., “Effects of three flavonoids from an ancient traditional chinese medicine radix puerariae on geriatric diseases,” Brain Circulation, vol. 4, no. 04, pp. 174–184, 2018. View at: Google Scholar
  6. W. Y. Tam, P. Chook, M. Qiao et al., “The efficacy and tolerability of adjunctive alternative herbal medicine (salvia miltiorrhiza and pueraria lobata) on vascular function and structure in coronary patients,” The Journal of Alternative and Complementary Medicine, vol. 15, no. 4, pp. 415–421, 2009. View at: Publisher Site | Google Scholar
  7. K. Woo, T. Yip, P. Chook et al., “Cardiovascular protective effects of adjunctive alternative medicine (salvia miltiorrhiza and pueraria lobata) in high-risk hypertension,” Evidence-Based Complement and Alternat Medicine, vol. 2013, Article ID 132912, 2013. View at: Publisher Site | Google Scholar
  8. Z. Chen and Xu. Hao, “Anti-inflammatory and immunomodulatory mechanism of tanshinone IIA for atherosclerosis,” Evidence-Based Complement and Alternat Medicine, vol. 3, Article ID 267976, 2014. View at: Publisher Site | Google Scholar
  9. S. Xu and P. Liu, “Tanshinone II-A: new perspectives for old remedies,” Expert Opinion on Therapeutic Patents, vol. 23, no. 2, pp. 149–153, 2013. View at: Publisher Site | Google Scholar
  10. L. Shuangmei, Y. Shicheng, X. Changshui et al., “Puerarin alleviates aggravated sympathoexcitatory response induced by myocardial ischemia via regulating P2X3 receptor in rat superior cervical ganglia,” Neurochemistry International, vol. 70, no. 1, pp. 39–49, 2014. View at: Google Scholar
  11. P. Nallasamy and A. C. Venkataraman, “Beneficial effect of genistein on lowering blood pressure and kidney toxicity in fructose-fed hypertensive rats,” The British Journal of Nutrition, vol. 109, no. 10, pp. 1806–1812, 2013. View at: Google Scholar
  12. H. Lam, W. Yam, K. Lau et al., “Antioxidative and vasodilative effects of danshen and gegen,” Journal of Molecular and Cellular Cardiology, vol. 38, p. 840, 2005. View at: Google Scholar
  13. F. F. Y. Lam, S. Y. Deng, E. S. K. Ng et al., “Mechanisms of the relaxant effect of a danshen and gegen formulation on rat isolated cerebral basilar artery,” Journal of Ethnopharmacology, vol. 132, no. 1, pp. 186–192, 2010. View at: Publisher Site | Google Scholar
  14. B. Zhang, X. Wang, and S. li, “An integrative platform of TCM network pharmacology and its application on a herbal formula, qing-luo-yin,” Evidence-Based Complement and Alternat Medicine, vol. 2013, Article ID 456747, 2013. View at: Publisher Site | Google Scholar
  15. D. C. Hao and P. G. Xiao, “Network pharmacology: a rosetta stone for traditional Chinese medicine,” Drug Development Research, vol. 75, no. 5, pp. 299–312, 2014. View at: Publisher Site | Google Scholar
  16. M. Yang, J. L. Chen, L. W. Xu et al., “Navigating traditional chinese medicine network pharmacology and computational tools,” Evidence-Based Complement and Alternat Medicine, vol. 2013, Article ID 731969, 2013. View at: Publisher Site | Google Scholar
  17. A. Y. Lee, W. Park, T.-W. Kang, M. H. Cha, and J. M. Chun, “Network pharmacology-based prediction of active compounds and molecular targets in yijin-tang acting on hyperlipidaemia and atherosclerosis,” Journal of Ethnopharmacology, vol. 221, pp. 151–159, 2018. View at: Publisher Site | Google Scholar
  18. W. Wang, T. Liu, L. Yang et al., “Study on the multi-targets mechanism of triphala on cardio-cerebral vascular diseases based on network pharmacology,” Biomedicine & Pharmacotherapy, vol. 116, Article ID 108994, 2019. View at: Publisher Site | Google Scholar
  19. J. Ru, P. Li, J. Wang et al., “TCMSP: a database of systems pharmacology for drug discovery from herbal medicines,” Journal of Cheminformatics, vol. 6, no. 13, 2014. View at: Publisher Site | Google Scholar
  20. The UniProt Consortium, “UniProt: the universal protein knowledgebase,” Nucleic Acids Research, vol. 45, pp. D158–D169, 2018. View at: Google Scholar
  21. Y. Wang, S. Zhang, F. Li et al., “Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics,” Nucleic Acids Research, vol. 48, no. D1, pp. D1031–D1041, 2020. View at: Google Scholar
  22. G. R. Brown, V. Hem, K. S. Katz et al., “Gene: a gene-centered information resource at NCBI,” Nucleic Acids Research, vol. 43, no. D1, pp. D36–D42, 2015. View at: Publisher Site | Google Scholar
  23. J. S. Amberger and A. Hamosh, “Searching online mendelian inheritance in man (OMIM): a knowledgebase of human genes and genetic phenotypes,” Current Protoc Bioinformatics, vol. 58, pp. 1.2.1–1.2.12, 2017. View at: Publisher Site | Google Scholar
  24. D. Glynn, B. T. Sherman, D. A. Hosack et al., “DAVID: database for annotation, visualization, and integrated discovery,” Genome Biology, vol. 4, no. 9, 2003. View at: Google Scholar
  25. C. V. Mering, M. Huynen, D. Jaeggi et al., “STRING: a database of predicted functional associations between proteins,” Nucleic Acids Research, vol. 1, no. 31, pp. 258–261, 2003. View at: Publisher Site | Google Scholar
  26. Y. Cui, C. Li, C. Zeng et al., “Tongmai yangxin pills anti-oxidative stress alleviates cisplatin-induced cardiotoxicity: network pharmacology analysis and experimental evidence,” Biomedicine & Pharmacotherapy, vol. 108, pp. 1081–1089, 2018. View at: Publisher Site | Google Scholar
  27. M. Hong, S. Li, N. Wang, H.-Y. Tan, F. Cheung, and Y. Feng, “A biomedical investigation of the hepatoprotective effect of radix salviae miltiorrhizae and network pharmacology-based prediction of the active compounds and molecular targets,” International Journal of Molecular Sciences, vol. 18, no. 3, p. 620, 2017. View at: Publisher Site | Google Scholar
  28. D. M. G. Oliveira, L. T. Aguiar, M. V. de Oliveira Limones et al., “Aerobic training efficacy in inflammation, neurotrophins, and function in chronic stroke persons: a randomized controlled trial protocol,” Journal of Stroke and Cerebrovascular Diseases, vol. 28, no. 2, pp. 418–424, 2019. View at: Publisher Site | Google Scholar
  29. S. Karaman, V.-M. Leppänen, and K. Alitalo, “Vascular endothelial growth factor signaling in development and disease,” Development, vol. 145, no. 14, Article ID 151019, 2018. View at: Publisher Site | Google Scholar
  30. Y. Ma, A. Zechariah, Y. Qu, and D. M. Hermann, “Effects of vascular endothelial growth factor in ischemic stroke,” Journal of Neuroscience Research, vol. 90, no. 10, pp. 1873–1882, 2012. View at: Publisher Site | Google Scholar
  31. S. Geiseler and C. Morland, “The janus face of VEGF in stroke,” International Journal of Molecular Sciences, vol. 19, no. 5, p. 1362, 2018. View at: Publisher Site | Google Scholar
  32. P. Robson-Ansley, E. Cockburn, I. Walshe et al., “The effect of exercise on plasma soluble IL-6 receptor concentration: a dichotomous response,” Exercise Immunology Review, vol. 16, pp. 56–76, 2010. View at: Google Scholar
  33. A. Rayasam, M. Hsu, G. Hernández et al., “Contrasting roles of immune cells in tissue injury and repair in stroke: the dark and bright side of immunity in the brain,” Neurochemistry International, vol. 107, pp. 104–116, 2017. View at: Publisher Site | Google Scholar
  34. A. Sugita, K. Kinoshita, A. Sakurai et al., “Systemic impact on secondary brain aggravation due to ischemia/reperfusion injury in post-cardiac arrest syndrome: a prospective observational study using high-mobility group box 1 protein,” Critical Care, vol. 21, no. 1, p. 247, 2017. View at: Publisher Site | Google Scholar
  35. M. L. Lindsey, “Assigning matrix metalloproteinase roles in ischaemic cardiac remodelling,” Nature Reviews Cardiology, vol. 15, no. 8, pp. 471–479, 2018. View at: Publisher Site | Google Scholar
  36. Z.-H. Yu, M. Cai, J. Xiang et al., “PI3K/Akt pathway contributes to neuroprotective effect of tongxinluo against focal cerebral ischemia and reperfusion injury in rats,” Journal of Ethnopharmacology, vol. 181, pp. 8–19, 2016. View at: Publisher Site | Google Scholar
  37. R. Lan, J. Xiang, Y. Zhang et al., “PI3K/Akt pathway contributes to neurovascular unit protection of xiao-xu-ming decoction against focal cerebral ischemia and reperfusion injury in rats,” Evidence-Based Complement and Alternat Medicine, vol. 2013, Article ID 459467, 2013. View at: Publisher Site | Google Scholar
  38. H. Endo, C. Nito, H. Kamada, T. Nishi, and P. H. Chan, “Activation of the akt/gsk3β signaling pathway mediates survival of vulnerable hippocampal neurons after transient global cerebral ischemia in rats,” Journal of Cerebral Blood Flow & Metabolism, vol. 26, no. 12, pp. 1479–1489, 2006. View at: Publisher Site | Google Scholar
  39. Y. J. Ma, C. Lu, C. F. Li et al., “Overexpression of HSPA12B protects against cerebral ischemia/reperfusion injury via a PI3K/Akt-dependent mechanism,” Biochimica et Biophysica Acta, vol. 1832, no. 1, pp. 57–66, 2013. View at: Google Scholar
  40. C. Liu, J. Wu, K. Xu et al., “Neuroprotection by baicalein in ischemic brain injury involves PTEN/AKT pathway,” Journal of Neurochemistry, vol. 112, no. 6, pp. 1500–1512, 2010. View at: Publisher Site | Google Scholar
  41. H. Zhao, T. Shimohata, J. Q. Wang et al., “Akt contributes to neuroprotection by hypothermia against cerebral ischemia in rats,” Journal of Neuroscience, vol. 25, no. 42, pp. 9794–9806, 2005. View at: Publisher Site | Google Scholar
  42. Y.-X. Zhou, H. Zhang, and C. Peng, “Puerarin: a review of pharmacological effects,” Phytotherapy Research, vol. 28, no. 7, pp. 961–975, 2014. View at: Publisher Site | Google Scholar
  43. M.-q. Zhang, Y.-l. Zheng, H. Chen et al., “Sodium tanshinone IIA sulfonate protects rat myocardium against ischemia-reperfusion injury via activation of PI3K/Akt/FOXO3A/Bim pathway,” Acta Pharmacologica Sinica, vol. 34, no. 11, pp. 1386–1396, 2013. View at: Publisher Site | Google Scholar
  44. E. Varfolomeev, T. Goncharov, H. Maecker et al., “Cellular inhibitors of apoptosis are global regulators of NF- B and MAPK activation by members of the TNF family of receptors,” Science Signaling, vol. 5, no. 216, p. ra22, 2012. View at: Publisher Site | Google Scholar
  45. S. Cagnin, M. Biscuola, C. Patuzzo et al., “Reconstruction and functional analysis of altered molecular pathways in human atherosclerotic arteries,” BMC Genomics, vol. 10, no. 1, p. 13, 2009. View at: Publisher Site | Google Scholar
  46. J. Feng, K. Anderson, Y. Liu, A. K. Singh, A. Ehsan, and F. W. Sellke, “Cyclooxygenase 2 contributes to bradykinin-induced microvascular responses in peripheral arterioles after cardiopulmonary bypass,” Journal of Surgical Research, vol. 218, pp. 246–252, 2017. View at: Publisher Site | Google Scholar

Copyright © 2020 Yang Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.